cjun
ntermin
kinas
jnk
subject
intens
interest
sinc
discoveri
earli
major
research
program
direct
screen
andor
design
jnkselect
inhibitor
test
potenti
drug
begin
review
consid
first
commerciallyavail
jnk
atpcompetit
inhibitor
focu
recent
studi
evalu
action
lung
brain
kidney
liver
follow
exposur
rang
stress
insult
includ
ischemiareperfus
mani
case
administr
prove
benefici
jnk
activ
also
follow
infect
next
consid
recent
exampl
demonstr
benefit
administr
viral
infect
addit
atpcompetit
jnk
inhibitor
describ
follow
high
throughput
screen
small
molecul
librari
inform
use
biolog
system
remain
limit
thu
inhibitor
requir
evalu
peptid
substratecompetit
atpnoncompetit
inhibitor
jnk
also
describ
discuss
recent
advanc
use
jnk
inhibitori
peptid
treatment
neuron
death
diabet
viral
infect
conclud
rais
number
question
consid
quest
jnkspecif
inhibitor
cjun
ntermin
kinas
jnk
initi
describ
earli
famili
serinethreonin
protein
kinas
activ
rang
stress
stimuli
abl
phosphoryl
ntermin
transactiv
domain
cjun
transcript
factor
phosphoryl
enhanc
cjundepend
transcript
event
mammalian
cell
research
reveal
three
jnk
gene
spliceform
well
rang
extern
stimuli
lead
jnk
activ
number
independ
approach
sinc
suggest
import
jnkdepend
signal
event
normal
develop
diseas
highlight
strike
benefici
phenotyp
jnk
gene
knockout
mice
diseas
model
includ
neuroprotect
stroke
improv
insulin
respons
diabet
review
inhibitor
use
increasingli
explor
biolog
function
jnk
mammalian
system
without
need
jnk
gene
knockout
review
explor
recent
develop
discoveri
jnk
inhibitor
potenti
treatment
human
diseas
first
focu
small
molecul
atpcompetit
jnk
inhibitor
summaris
fig
initi
discuss
centr
develop
signal
pharmaceuticalscelgen
addit
provid
brief
overview
increas
number
small
molecul
atpcompetit
jnk
inhibitor
describ
publish
literatur
discuss
recent
advanc
use
atpnoncompetit
jnk
inhibitori
peptid
inhibitor
also
highlight
fig
lastli
consid
question
aris
develop
jnk
inhibitor
possibl
therapeut
applic
question
centr
control
need
establish
specif
action
jnk
inhibitor
whether
jnk
isoformselect
inhibitor
possibl
desir
whether
compound
offtarget
effect
inhibit
jnk
concern
accompani
chronic
use
jnkspecif
inhibitor
work
need
address
issu
howev
demonstr
efficaci
current
gener
jnk
inhibitor
improv
outcom
diseas
model
suggest
effort
worthwhil
late
small
molecul
jnk
inhibitor
anthra
one
report
follow
screen
proprietari
librari
celgenesign
pharmaceut
inhibitor
activ
toward
cjun
transactiv
domain
chemic
structur
shown
tabl
alongsid
structur
small
molecul
inhibitor
jnk
discuss
subsequ
section
review
highli
planar
natur
poor
solubl
aqueou
solut
consequ
anthrapyrazolon
core
structur
note
initi
descript
jnk
inhibit
observ
revers
atpcompetit
show
ic
valu
jnk
inhibit
rang
nm
see
tabl
n
select
relat
mitogenactiv
protein
kinas
mapk
select
anoth
protein
kinas
test
result
suggest
high
affin
specif
interact
residu
jnk
atpbind
site
interact
jnk
explor
follow
cocrystallis
result
structur
protein
databas
pdb
shown
fig
residu
conserv
relat
mapk
highlight
specif
residu
produc
narrow
atpbind
pocket
jnk
accommod
planar
molecul
predict
contribut
specif
toward
jnk
mapk
although
predict
investig
mutagenesi
studi
target
jnk
atpbind
site
residu
singl
mutat
significantli
alter
bind
jnk
work
need
evalu
whether
mutat
residu
combin
might
produc
strike
effect
direct
evid
residu
interact
drive
structur
refin
increas
inhibitor
affin
specif
initi
test
biolog
efficaci
stimul
jurkat
cell
cultur
cjun
phosphoryl
inhibit
ic
concentr
requir
intracellular
effect
therefor
significantli
higher
vitro
ic
valu
estim
purifi
jnk
protein
nm
see
tabl
differ
attribut
atp
concentr
compet
differ
assay
vitro
biochem
assay
perform
atp
concentr
lower
would
normal
found
vivo
thu
intracellular
ic
valu
higher
observ
vitro
use
evalu
jnkdepend
event
cell
grown
rapidli
sinc
n
public
report
use
cell
vivo
restrict
discuss
two
broad
area
highlight
differ
area
possibl
therapeut
applic
jnk
inhibitor
begin
consid
effect
enhanc
recoveri
follow
ischemiareperfus
damag
insult
varieti
tissu
type
underli
theme
emerg
action
prevent
cell
death
describ
inhibit
number
proapoptot
event
activ
proapoptot
famili
member
releas
mitochondri
cytochrom
c
cell
cytosol
activ
proapoptot
caspas
famili
proteas
reader
refer
recent
excel
review
apoptosi
detail
hallmark
cell
death
process
case
also
appear
modul
immun
cell
respons
thu
provid
benefici
effect
consid
possibl
therapeut
applic
treatment
infecti
diseas
notabl
action
alter
outcom
viral
diseas
taken
fig
gener
overview
reaction
catalys
activ
jnk
highlight
differ
class
jnk
inhibitor
describ
date
jnk
activ
via
specif
protein
kinas
cascad
eukaryot
cell
expos
cytokin
stress
activ
jnk
catalys
phosphoryl
reaction
residu
atp
transfer
rang
protein
substrat
review
centr
jnk
inhibitor
describ
publish
literatur
inhibitor
divid
directli
interfer
atpbind
thu
term
atpcompetit
jnk
inhibitori
peptid
compet
protein
substrat
thu
term
atpnoncompetit
high
throughput
screen
abbott
compound
collect
use
activ
assay
follow
test
cellbas
assay
inhibit
tumour
ic
nm
structur
relat
compound
continu
next
page
high
throughput
screen
abbott
compound
collect
use
activ
assay
follow
ration
structur
design
test
cellbas
assay
inhibit
tumour
necrosisfactor
stimul
cjun
phosphoryl
ic
nm
togeth
studi
suggest
administr
benefici
rang
therapeut
applic
jnk
activ
follow
insult
ischemiareperfus
mani
tissu
includ
lung
kidney
liver
brain
heart
lung
challeng
face
transplant
remain
primari
graft
failur
follow
ischemiareperfus
injuri
initi
remov
subsequ
transplant
surgeri
inclus
preserv
reperfus
solut
reduc
lung
injuri
visualis
directli
histolog
examin
lung
tissu
assess
apoptot
cell
number
benefit
accompani
improv
biochem
marker
decreas
releas
total
protein
lactat
dehydrogenas
tumour
necrosi
bronchoalveolar
lavag
fluid
indic
mainten
tissu
integr
despit
ischemia
reperfus
insult
form
lung
insult
administr
also
benefici
administr
h
smoke
inhal
decreas
airway
cell
apoptosi
decreas
mucou
plug
lower
influx
inflammatori
cell
decreas
releas
cytokin
improv
anim
surviv
vivo
data
suggest
critic
role
jnk
smokeinduc
lung
injuri
highlight
benefici
effect
similarli
administr
implic
jnk
regul
express
acut
phase
protein
pentraxin
lung
respons
proinflammatori
cytokin
tumour
necrosi
factor
higher
level
pentraxin
exacerb
lung
injuri
jnk
inhibit
expect
attract
therapeut
approach
protect
lung
increas
tumour
necrosi
factor
level
accompani
mani
inflammatori
insult
ischemiareperfus
insult
also
accompani
renal
transplant
surgeri
renal
failur
trauma
direct
protect
effect
kidney
ischemia
reperfus
observ
attribut
jnk
inhibit
suppress
apoptot
cell
death
event
fa
ligandiniti
extrins
pathway
involv
macrophag
renal
tissu
injuri
vivo
also
suggest
macrophag
accumul
promin
featur
form
human
glomerulonephr
correl
renal
dysfunct
exposur
bone
marrowderiv
macrophag
prior
transfer
sheep
model
glomerulonephr
caus
reduct
proteinuria
thu
highlight
critic
role
jnk
signal
pathway
macrophagemedi
renal
injuri
benefit
jnk
inhibit
ischemiareperfus
may
therefor
includ
alter
inflammatori
cell
respons
initi
damag
possibl
benefit
liver
follow
insult
also
demonstr
mark
protect
effect
observ
acetaminopheninduc
toxic
vitro
vivo
action
observ
block
apoptot
cell
death
extend
recent
studi
acut
hepat
failur
follow
paracetamol
poison
administr
vivo
markedli
reduc
mortal
hepat
tumour
necrosi
factor
product
similarli
subcutan
inject
prior
h
h
insult
reduc
hepatocyt
apoptosi
suppress
lethal
decreas
elev
serum
marker
liver
damag
experiment
model
fulmin
hepat
failur
contrast
administr
protect
carbon
tetrachlorid
fig
structur
jnk
complex
atpcompetit
inhibitor
cocrystallis
result
structur
record
protein
databas
pdb
residu
conserv
name
highlight
although
residu
predict
like
contribut
specif
toward
mapk
subsequ
mutagenesi
studi
work
requir
evalu
residu
make
major
contribut
bind
concanavalin
toxic
highlight
jnk
inhibit
benefici
form
hepat
injuri
instead
suggest
target
stressiniti
event
test
altern
therapeut
approach
similar
potenti
extrem
problem
also
face
strive
improv
surviv
neuron
follow
insult
brain
treatment
prevent
cell
death
follow
ischemia
ischemiareperfus
brain
one
exampl
decreas
neuron
apoptosi
induc
global
ischemiareperfus
hippocamp
subregion
specif
suppress
express
fa
ligand
initi
extrins
death
pathway
transloc
proapoptot
protein
bax
mitochondria
releas
cytochrom
c
cytosol
activ
proapoptot
caspas
similarli
model
earli
brain
injuri
subarachnoid
hemorrhag
administ
intraperiton
h
h
haemorrhag
demonstr
benefit
suppress
caspas
activ
concomit
neuron
injuri
improv
bloodbrain
barrier
preserv
reduc
brain
swell
improv
neurolog
function
also
prevent
apoptosi
dopaminerg
neuron
mptp
model
parkinson
diseas
well
neuron
acut
injuri
accompani
spinal
cord
trauma
taken
togeth
result
support
develop
jnk
inhibitor
neuroprotect
agent
use
rang
brain
insult
contrast
posit
find
support
benefit
administr
describ
preced
paragraph
detriment
effect
report
ischemiareperfus
injuri
tissu
cell
type
exampl
administ
onset
partial
hepat
ischemia
subsequ
reperfus
event
number
marker
liver
damag
serum
alanin
aminotransferas
level
increas
accompani
deterior
liver
histolog
increas
neutrophil
infiltr
augment
oxid
stress
reperfus
liver
tissu
thu
detriment
effect
liver
appear
mediat
least
partial
via
circul
immun
cell
exacerb
detriment
effect
also
detriment
effect
note
cell
heart
significantli
enhanc
activ
proapoptot
proteas
increas
number
apoptot
cardiac
myocyt
cultur
respons
energi
deplet
follow
exposur
potassium
cyanid
similarli
chronic
treatment
vivo
cardiomyopath
hamster
model
heart
failur
increas
number
apoptot
tunelposit
myocyt
area
interstiti
fibrosi
accompani
enhanc
left
ventricular
chamber
dilat
dysfunct
indic
neg
effect
cardiac
structur
function
whilst
result
suggest
role
jnk
cardiac
myocyt
surviv
contradict
observ
protect
cardiac
myocyt
cell
death
follow
stimul
emphas
cardiac
effect
must
evalu
rang
differ
insult
patholog
condit
addit
studi
need
explor
alter
balanc
death
surviv
differ
cell
type
biochem
level
cell
contextdepend
differ
note
preced
paragraph
may
reflect
differ
express
andor
localis
jnk
substrat
within
variou
cell
type
addit
also
becom
clearer
defin
impact
jnk
signal
immun
cell
function
critic
understand
diseas
signific
immunolog
respons
differ
observ
may
also
reflect
variou
administr
insult
protocol
employ
studi
concentr
achiev
vivo
avail
addit
jnk
inhibitor
allow
issu
address
directli
increasingli
shown
viral
infect
lead
jnk
activ
exampl
includ
infect
epsteinbarr
viru
herp
simplex
viru
reoviru
kaposi
sarcoma
viru
varicellazost
viru
whilst
exact
mechan
lead
jnk
activ
remain
evalu
mani
case
interest
kaposi
sarcoma
viru
encod
viral
kinas
interact
jnk
well
upstream
jnk
pathway
kinas
express
lead
phosphoryl
activ
thu
jnk
activ
intervent
studi
primarili
cultur
cell
vitro
support
role
jnk
activ
viral
infect
process
andor
subsequ
cellular
event
follow
paragraph
discuss
result
recent
studi
evalu
effect
model
viral
infect
suggest
jnk
inhibitor
may
provid
new
therapeut
intervent
number
situat
follow
exposur
viru
viral
protein
treatment
prevent
viralinduc
cell
death
consist
studi
discuss
preced
section
highlight
could
prevent
cell
death
mani
tissu
follow
rang
differ
stress
specif
treatment
prevent
apoptot
death
follow
exposur
human
monocyt
cell
human
immunodefici
viru
hiv
accessori
protein
viral
protein
vpr
similar
posit
effect
protect
cell
death
observ
treatment
either
rescu
influenza
epitopespecif
human
cytolyt
lymphocyt
activationinduc
cell
death
prevent
death
cultur
hippocamp
cell
expos
herp
simplex
type
viru
convers
inhibit
prolifer
primari
erythroleukem
cell
isol
friend
spleen
focusform
virusinfect
mice
furthermor
cell
line
establish
anim
caus
signific
apoptosi
well
increas
fraction
cell
phase
cell
cycl
undergo
endoredupl
latter
data
suggest
jnk
play
import
role
cell
prolifer
andor
surviv
erythroleukemia
cell
thu
administr
could
provid
novel
approach
treatment
viralinduc
erythroleukemia
exampl
viral
infect
use
alter
viral
replic
cellular
persist
exampl
rotaviru
doublestrand
rna
viru
affect
gastrointestin
system
result
vomit
diarrhoea
use
combin
mapk
inhibitor
suggest
maxim
rotavirusinduc
cjun
transcript
requir
jnk
activ
significantli
jnk
requir
rotaviru
replic
viral
structur
antigen
express
similarli
use
togeth
inhibitor
phosphatidylinositol
inhibit
establish
persist
sarscov
infect
vero
cell
clearli
mani
opportun
evalu
act
concert
inhibitor
intracellular
signal
pathway
modul
aspect
viral
biolog
appropri
therapeut
strategi
may
ultim
requir
combin
therapi
signal
transduct
modul
despit
success
also
situat
treatment
benefici
emphas
need
caution
exampl
use
significantli
chang
diseas
progress
follow
infect
coxsackieviru
enteroviru
picornaviru
famili
common
human
pathogen
associ
myocard
idiopath
dilat
cardiomyopathi
reduc
phosphoryl
activ
transcript
factor
alter
viral
protein
synthesi
viral
progeni
releas
cell
death
activ
infect
cell
contrast
mapk
inhibitor
alter
progeni
releas
thu
remain
critic
test
effect
rang
differ
viru
type
cellular
effect
treatment
may
also
alter
gene
express
chang
signific
effect
viru
structur
andor
life
cycl
hepat
c
viru
nonstructur
protein
proteinexpress
cell
exposur
abolish
number
transcript
factor
activ
notabl
inhibit
cjun
express
inhibit
cell
growth
similarli
block
cytomegaloviru
induct
relb
promot
activ
nih
cultur
smooth
muscl
cell
furthermor
nuclear
localis
viral
encod
protein
may
regul
jnk
seen
human
papillomaviru
dna
helicas
thu
newli
recogn
role
jnk
may
open
new
antivir
strategi
use
jnk
inhibitor
despit
obviou
success
repeat
use
vitro
vivo
system
sceptic
surround
continu
use
particularli
specif
jnk
inhibit
close
evalu
despit
initi
claim
select
littl
inhibit
shown
test
protein
kinas
inflammatori
enzym
subsequ
test
shown
inhibit
test
protein
kinas
notabl
serum
glucocorticoidregul
kinas
ribosom
kinas
ampdepend
protein
kinas
cyclin
depend
kinas
casein
kinas
dualspecif
tyrosineregul
kinas
inhibit
greater
extent
inhibit
observ
jnk
addit
data
show
bind
rang
kinas
test
protein
kinas
phage
interact
screen
assay
suggest
may
mani
addit
kinas
target
despit
concern
rais
specif
valu
therapeut
agent
confirm
continu
use
vivo
minim
toxic
undesir
sideeffect
caution
exercis
core
anthrapyrazol
structur
consid
anthrapyrazol
use
anticanc
agent
due
toxic
effect
associ
reactiv
oxygen
speci
ro
product
topoisomeras
inhibit
dnainteract
thu
administr
vivo
may
associ
similar
toxic
would
undesir
aim
prevent
cell
death
greater
concern
effect
longterm
dose
evalu
thu
continu
develop
new
therapeut
therapeut
lead
requir
evalu
show
toxic
effect
via
jnkindepend
action
second
gener
atpcompetit
anthrapyrazolon
jnk
inhibitor
also
develop
celgen
base
chemistri
despit
limit
publicli
avail
detail
compound
use
celgen
state
complet
phase
trial
healthi
volunt
celgen
also
evalu
phase
ii
clinic
trial
acut
myelogen
leukemia
given
anticanc
activ
anthrapyrazol
evid
support
action
via
jnk
inhibit
requir
shown
efficaci
experiment
model
immuneinduc
renal
injuri
specif
treatment
rat
antiglomerular
basement
membran
diseas
model
reduc
proteinuria
first
h
rapid
transient
neutrophil
influx
affect
continu
treatment
suppress
glomerular
tubulointerstiti
damag
usual
seen
day
effect
upon
glomerular
macrophag
infiltr
day
propos
protect
due
modul
macrophag
activ
thu
jnk
signal
would
appear
promot
renal
injuri
acut
progress
rat
antiglomerular
basement
membran
diseas
jnk
inhibitor
may
novel
therapeut
approach
treatment
human
glomerulonephr
similarli
kidney
obstruct
significantli
reduc
tubular
apoptosi
inhibit
renal
fibrosi
shown
interstiti
myofibroblast
accumul
collagen
iv
deposit
latter
effect
attribut
suppress
gene
transcript
profibrot
factor
tumour
growth
connect
tissu
growth
factor
relat
compound
also
use
model
liver
injuri
thu
inclus
jnk
inhibitori
compound
hepat
warm
ischemiareperfus
injuri
model
significantli
improv
surviv
rate
decreas
mortal
correl
improv
hepat
histolog
compound
significantli
inhibit
pericentr
necrosi
neutrophil
infiltr
apoptosi
hepatocyt
sinusoid
endotheli
cell
decreas
activ
cytochrom
c
releas
mitochondria
lower
level
lipid
peroxid
similar
benefici
effect
note
follow
cold
ischem
storag
liver
tissu
follow
warm
reperfus
benefit
would
expect
upon
inclus
jnk
inhibitori
compound
storag
transport
solut
use
liver
transplant
surgeri
confirm
jnk
inhibit
critic
benefit
associ
treatment
addit
intervent
direct
toward
jnk
activ
vivo
need
follow
paragraph
new
class
atpcompetit
jnk
inhibitor
describ
allow
benefit
jnk
inhibit
new
therapeut
approach
explor
date
small
molecul
jnk
inhibitor
recent
disclos
publicli
avail
scientif
literatur
receiv
attent
direct
toward
section
ten
addit
jnk
inhibitor
briefli
overview
summari
inhibitor
togeth
chemic
structur
provid
tabl
summari
list
chronolog
first
publish
report
inhibitor
also
present
structur
inhibitor
cocrystallis
jnk
protein
fig
structur
suggest
atpcompetit
natur
inhibitor
small
molecul
jnk
inhibitor
includ
exampl
diarylimidazol
report
scientist
merck
benzoylaminomethyl
thiophen
sulfonamid
serono
dihydropyrroloimidazol
eisai
acetonitril
also
known
serono
anilinoindazol
anilinobipyridin
astra
zeneca
well
pyrazoloquinolinon
aminopyridin
pyridin
carboxamid
anilinopyrimidin
abbott
compound
larg
discov
high
throughput
screen
compound
librari
typic
test
action
vitro
kinas
assay
purifi
jnk
subsequ
structureact
studi
test
cell
cultur
model
allow
refin
inhibitor
notabl
differ
approach
also
shown
refin
inhibitor
increas
potenc
toward
jnk
activ
rather
continu
rescreen
librari
directli
jnk
inhibitor
inhibitor
also
report
show
select
toward
maxim
differ
approxim
seen
anilinoindazol
higher
affin
remain
critic
evalu
biolog
action
new
jnk
inhibitor
limit
report
test
jnk
inhibitor
perfus
organ
system
vivo
shown
mix
result
therapeut
potenti
jnk
inhibitor
support
find
model
rheumatoid
arthriti
well
cerebr
cardiac
ischemia
undisclos
claim
benefit
model
inflamm
diabet
contrast
haemodynam
effect
report
carboxamidebas
jnk
inhibitor
suggest
caution
may
warrant
whether
undesir
side
effect
aris
jnkdepend
independ
inhibitor
action
must
address
ideal
effect
mani
structur
unrel
jnk
inhibitori
compound
compar
determin
jnkindepend
action
success
chemic
librari
screen
identifi
jnk
inhibitori
molecul
rais
possibl
addit
jnk
inhibitor
found
sourc
screen
natur
extract
reveal
extract
new
guinea
vine
gnetum
latifolium
vitro
inhibitor
purif
reveal
jnk
inhibitori
compon
latifolian
b
tabl
compound
form
part
alkaloid
structur
class
distribut
across
mani
plant
famili
energyminimis
three
dimension
structur
latifolian
determin
togeth
ic
valu
toward
tabl
studi
includ
kinet
structur
analys
address
whether
latifolian
atpcompetit
jnk
inhibitor
whether
jnk
isoform
target
equal
molecul
interact
jnk
protein
inform
could
direct
develop
new
class
jnk
inhibitor
exploit
essenti
structur
featur
latifolian
without
complex
structur
recent
review
peptid
inhibitor
protein
kinas
deriv
direct
interact
partner
protein
kinas
substrat
cellperm
peptid
jnk
inhibitor
deriv
jnk
substrat
cjun
sequenc
peptid
shown
tabl
cjun
interact
directli
jnk
peptid
would
compet
directli
cjun
substrat
bind
peptid
use
highlight
complex
jnkcjunmedi
gene
regul
respons
interest
differ
observ
effect
jnk
inhibitori
peptid
atpcompetit
inhibitor
compar
exampl
interleukininduc
gene
gene
regul
presenc
either
cjun
peptid
gene
regul
cjun
peptid
gene
affect
cjun
peptid
gene
affect
whether
differ
reflect
offtarget
effect
differ
inhibitor
mode
action
compartmentalis
stabil
inhibitor
remain
address
scaffold
protein
known
jnkinteract
protein
jip
form
addit
import
featur
jnk
pathway
note
first
describ
inhibit
jnk
prevent
jnk
nuclear
transloc
short
conserv
sequenc
also
identifi
critic
interact
short
jipderiv
peptid
subsequ
shown
inhibit
jnk
activ
vitro
peptid
cellperm
form
conjug
tat
peptid
use
investig
effect
jnk
inhibit
cell
vivo
sequenc
commonli
use
cellperm
jnk
inhibitori
peptid
deriv
jip
shown
tabl
includ
convent
lamino
acid
contain
peptid
tijip
tattijip
ljnki
well
damino
acidcontain
retroinverso
peptid
djnki
jipderiv
peptid
inhibitor
shown
kinet
act
protein
substratecompetit
manner
cocrystallis
mutagenesi
studi
bind
directli
put
protein
substrat
dock
domain
jnk
recent
peptid
use
evalu
kinet
mechan
result
provid
import
insight
biochemistri
jnk
includ
protein
substrat
bind
primarili
due
distal
contact
dock
groov
minim
alloster
commun
proteinsubstr
dock
site
atp
bind
site
activ
catalyt
centr
phosphoryl
proce
via
random
sequenti
mechan
recent
review
evalu
studi
use
cellperm
form
jnk
inhibitori
jipbas
peptid
highlight
success
peptid
block
pancreat
death
cerebr
ischemiastrok
hear
loss
induc
aminoglycosid
acoust
trauma
latter
extend
recent
studi
restrict
attent
report
efficaci
jnk
inhibitori
peptid
appear
last
year
sinc
review
begin
recent
studi
effect
neuron
cell
neuropath
pain
often
accompani
nerv
damag
option
current
avail
effect
treatment
search
possibl
target
therapeut
intervent
treatment
pain
note
spinal
nerv
ligat
result
slow
persist
activ
jnk
spinal
cord
astrocyt
intrathec
infus
djnki
spinal
fluid
alter
basal
mechan
threshold
prior
injuri
prevent
mechan
allodynia
day
note
pain
return
infus
protocol
end
thu
djnki
treatment
provid
temporari
pain
relief
addit
strategi
need
identifi
target
longterm
pain
relief
consist
observ
benefit
djnki
ischemia
reperfus
particularli
brain
tattijip
also
prevent
apoptot
death
necrot
death
neuron
cultur
apoptosi
inhibit
nuclear
nonnuclear
pathway
import
necrosi
exact
jnkmediat
event
remain
defin
number
key
find
direct
futur
studi
specif
tattijip
appli
prior
transient
exposur
glutam
mimic
excitotox
anilinopyrimidin
abbott
complex
jnk
inhibitori
peptid
deriv
also
indic
accompani
stroke
prevent
mitochondri
ro
gener
increas
cytosol
calcium
concentr
maintain
mitochondri
membran
potenti
basic
principl
model
involv
jnk
activ
necrosi
illustr
fig
recent
use
jnk
knockout
cell
shown
jnk
mediat
necrot
death
via
sustain
activ
poli
adpribos
follow
exposur
ro
direct
vitro
phosphoryl
assay
suggest
ad
grow
list
jnk
substrat
interest
test
whether
jnk
inhibitori
peptid
inhibit
action
jnk
whether
modifi
peptid
antagonist
requir
continu
strategi
reduc
neuron
cell
death
recent
studi
shown
djnki
effect
treatment
reovirusinduc
enceph
infect
achiev
direct
inject
high
dose
viru
brain
tissu
neonat
rat
subsequ
evalu
brain
patholog
tdqsrpvqpflnlttprkprpprrrqrrkkrg
determin
less
potent
ljnki
cellperm
vector
sequenc
underlin
b
amino
acid
denot
without
capit
damino
acid
form
latifolian
b
high
throughput
screen
natur
extract
inhibitor
activ
vitro
ic
surviv
despit
posit
find
djnki
deliv
intraperiton
viral
infect
number
interest
observ
consid
notabl
symptom
myocard
block
djnki
thu
reovir
infect
remain
lethal
due
cardiac
effect
address
whether
jnk
activ
also
underli
cardiac
patholog
whether
djnki
inhibit
jnk
activ
heart
posit
effect
djnki
heart
reduc
ischemiareperfus
injuri
infarct
size
vivo
recent
report
deliv
prior
onset
ischemia
latter
studi
djnki
deliv
time
reperfus
prevent
apoptosi
thu
limit
cardiac
infarct
size
intriguingli
improv
function
recoveri
reason
underli
discrep
cardiac
cell
death
infarct
zone
function
perform
heart
requir
evalu
jnk
inhibitori
peptid
also
allow
greater
evalu
role
jnk
infect
virus
jnk
inhibit
ljnki
result
increas
varicellazost
viru
replic
melanoma
cell
wherea
strong
decreas
viru
replic
observ
inhibit
mapk
note
howev
recent
studi
shown
caus
dosedepend
reduct
varicellazost
viru
yield
primari
fibroblast
reason
discrep
requir
evalu
may
includ
differ
cell
type
evalu
well
differ
mechan
action
atpcompetit
versu
atpnoncompetit
inhibitor
recent
studi
show
alter
immun
respons
follow
knockout
influenc
malari
infect
suggest
jnk
inhibitor
may
far
greater
use
treatment
rang
infecti
diseas
benefit
lower
jnkdepend
signal
diabet
first
seen
jnk
gene
knockout
studi
extend
observ
intraperiton
administr
jnk
inhibitori
peptid
improv
insulin
resist
glucos
toler
diabet
mice
jnk
inhibitori
peptid
also
test
effect
pancreat
islet
transplant
isol
process
subsequ
clinic
transplant
islet
subject
sever
advers
condit
impair
surviv
ultim
contribut
graft
failur
intraport
inject
jnk
inhibitori
peptid
islet
transplant
reduc
jnk
activ
insulin
target
organ
prevent
islet
graft
loss
immedi
transplant
improv
islet
transplant
outcom
thu
show
valu
jnk
inhibit
procedur
support
independ
observ
djnki
confer
protect
apoptosi
induc
islet
prepar
subsequ
exposur
controversi
remain
area
islet
preserv
recent
report
suggest
ljnki
djnki
would
provid
protect
toxic
damino
acidcontain
peptid
paradox
activ
jnk
mapk
follow
exposur
islet
djnki
suggest
underli
observ
detriment
effect
work
need
character
detriment
effect
defin
damino
acidcontain
peptid
may
toxic
howev
extend
halflif
jnk
inhibitori
peptid
may
alway
necessari
desir
therapeut
effect
exampl
ljnki
limit
lung
ischemiareperfus
damag
damino
acidcontain
peptid
necessari
system
rapid
acut
treatment
desir
prolong
vivo
halflif
offer
damino
acidcontain
peptid
may
requir
lastli
consid
peptid
inhibitor
may
advanc
clinic
trial
xigen
report
phase
trial
djnki
addit
demonstr
efficaci
jnk
inhibitori
peptid
import
optimis
vivo
cellperm
deliveri
strategi
particularli
cytotox
effect
cellperm
peptid
note
despit
import
advanc
recent
year
develop
jnk
atpcompetit
atpnoncompetit
inhibitor
mani
question
also
arisen
centr
control
need
establish
jnk
inhibitor
specif
whether
jnk
isoformselect
inhibitor
possibl
desir
whether
compound
may
offtarget
effect
inhibit
jnk
concern
may
accompani
chronic
use
jnk
inhibitor
conclud
review
briefli
consid
question
may
direct
research
effort
discov
improv
jnk
inhibitor
control
need
establish
jnk
inhibitor
specif
test
small
molecul
inhibitor
panel
protein
kinas
activ
assay
proteininteract
studi
emphas
offtarget
effect
alway
consid
particularli
earliest
stage
inhibitordrug
develop
although
simpl
concord
effect
fig
calcium
reactiv
oxygen
speci
ro
primari
driver
jnkdepend
necrot
cell
death
model
calcium
reactiv
oxygen
speci
ro
involv
amplif
cycl
lead
cell
death
calcium
overload
mitochondria
caus
ro
gener
ro
turn
increas
intracellular
calcium
directli
activ
calcium
channel
increas
membran
permeabl
lipid
peroxid
inactiv
calcium
remov
transport
jnk
inhibitor
break
cycl
attenu
increas
ro
calcium
observ
put
jnk
inhibitor
phenotyp
jnk
gene
knockout
anim
may
initi
support
specif
inhibitor
action
use
interpret
jnk
knockout
anim
complic
need
target
differ
jnk
gene
function
redund
isoform
robust
approach
combin
genet
pharmacolog
approach
evalu
protein
kinas
specif
modif
atpbind
pocket
protein
kinas
interest
socal
gatekeep
residu
allow
interact
bulki
atp
analogu
may
act
either
substrat
inhibitor
approach
aid
jnk
substrat
identif
recent
use
inhibit
jnk
defin
action
determin
jnk
activ
time
cours
affect
downstream
signal
consequ
phenotyp
mice
jnk
isoformselect
target
appear
benefici
see
review
although
high
sequenc
structur
similar
suggest
may
difficult
achiev
small
molecul
inhibitor
vivo
rna
interfer
rnai
remain
option
recent
use
evalu
specif
role
insulin
resist
mous
model
dietinduc
diabet
adenovir
deliveri
rnai
result
almost
complet
knockdown
hepat
level
without
affect
tissu
examin
whilst
accompani
reduc
circul
glucos
level
enhanc
insulin
signal
vitro
plasma
triglycerid
level
elev
appear
result
alter
express
sever
cluster
gene
involv
glycolysi
triglycerid
synthesi
pathway
earlier
studi
use
jnk
inhibitor
overexpress
dominantneg
jnk
mutant
gene
knockout
studi
eg
observ
similar
chang
remain
establish
strike
differ
compar
small
molecul
inhibit
genet
ablat
approach
recent
highlight
specif
jnk
attribut
compens
absenc
lead
enhanc
signal
inhibitor
initi
direct
toward
target
cell
may
also
interfer
jnk
action
recent
exampl
show
discoveri
antihepat
c
viru
compound
propyl
nicotinamid
inhibit
vascular
endotheli
growth
factor
receptor
kinas
well
jnk
activ
similarli
known
inhibitor
cyclindepend
kinas
glycogen
synthas
kinas
also
inhibit
jnk
rais
question
whether
action
inhibit
apoptosi
due
action
jnk
cyclindepend
kinas
glycogen
synthas
kinas
alon
combin
similarli
neuroprotect
thiosemicarbazon
may
exert
action
protect
glutam
toxic
via
inhibit
jnk
leflunomid
may
protect
acetaminopheninduc
liver
necrot
injuri
jnk
inhibit
embryon
lethal
mice
see
review
suggest
critic
role
jnk
develop
homeostasi
jnk
implic
critic
regul
neurit
format
neuron
axon
format
recent
suggest
jnk
regul
event
associ
health
degener
motoneuron
furthermor
jnk
may
play
protect
role
demonstr
thrombininduc
ischem
toler
brain
jnk
may
aid
regul
circadian
rhythm
role
suggest
chronic
jnk
inhibit
may
desir
therefor
remain
challeng
least
short
term
defin
rang
jnk
action
cell
like
mani
divers
shortterm
use
jnk
inhibitor
remain
attract
option
number
diseas
increas
avail
jnk
inhibitor
allow
rapid
progress
determin
inhibitor
efficaci
